AB
FHTX icon

Amalgamated Bank’s Foghorn Therapeutics FHTX Stock Holding History

Amalgamated Bank’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,046
Closed -$6K – 2044
2025
Q4 		$6K Buy
1,046
+365
+54% +$1.66K ﹤0.01% 2638
2025
Q3 		$3K Hold
681
– – ﹤0.01% 2889
2025
Q2 		$3K Hold
681
– – ﹤0.01% 2910
2025
Q1 		$2K Hold
681
– – ﹤0.01% 2838
2024
Q4 		$3K Hold
681
– – ﹤0.01% 2845
2024
Q3 		$6K Hold
681
– – ﹤0.01% 2689
2024
Q2 		$4K Hold
681
– – ﹤0.01% 2845
2024
Q1 		$5K Sell
681
-2,193
-76% -$12.2K ﹤0.01% 2712
2023
Q4 		$19K Sell
2,874
-203
-7% -$876 ﹤0.01% 2674
2023
Q3 		$15K Hold
3,077
– – ﹤0.01% 2779
2023
Q2 		$22K Buy
3,077
+295
+11% +$2.06K ﹤0.01% 2692
2023
Q1 		$17K Sell
2,782
-423
-13% -$2.77K ﹤0.01% 2697
2022
Q4 		$20K Hold
3,205
– – ﹤0.01% 2749
2022
Q3 		$27K Buy
3,205
+49
+2% +$631 ﹤0.01% 2718
2022
Q2 		$43K Buy
3,156
+655
+26% +$8.45K ﹤0.01% 2557
2022
Q1 		$38K Buy
+2,501
New +$34.3K ﹤0.01% 2590

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Amalgamated Bank's FHTX Position: Q1 2026 in Review

Amalgamated Bank sold out of Foghorn Therapeutics (FHTX) in Q1 2026, closing a stake of 1,046 shares — an estimated $6K sold.

Amalgamated Bank first reported a position in FHTX in Q1 2022 and held it in 16 quarters. The position peaked at $43K in Q2 2022. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Amalgamated Bank reported no remaining Foghorn Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,046 Foghorn Therapeutics shares in Q1 2026, an estimated $6K.
  • Amalgamated Bank first reported a position in Foghorn Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Foghorn Therapeutics position peaked at $43K in Q2 2022.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.